LY900014 + Insulin Lispro
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 1
Conditions
Diabetes Mellitus, Type 1
Trial Timeline
Feb 25, 2020 → Aug 10, 2020
NCT ID
NCT04276207About LY900014 + Insulin Lispro
LY900014 + Insulin Lispro is a phase 1 stage product being developed by Eli Lilly for Diabetes Mellitus, Type 1. The current trial status is completed. This product is registered under clinical trial identifier NCT04276207. Target conditions include Diabetes Mellitus, Type 1.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (16)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04276207 | Phase 1 | Completed |
| NCT04049123 | Phase 1 | Completed |
| NCT03760640 | Phase 2 | Completed |
| NCT03465878 | Phase 1 | Completed |
| NCT03433677 | Phase 3 | Completed |
| NCT03407118 | Phase 1 | Completed |
| NCT03341299 | Phase 1 | Completed |
| NCT03341312 | Phase 1 | Completed |
| NCT03286751 | Phase 1 | Completed |
| NCT03305822 | Phase 1 | Completed |
| NCT03166124 | Phase 1 | Completed |
| NCT02942654 | Phase 1 | Completed |
| NCT02703337 | Phase 1 | Completed |
| NCT02703324 | Phase 1 | Completed |
| NCT02703350 | Phase 1 | Completed |
| NCT02317575 | Phase 1 | Completed |
Competing Products
20 competing products in Diabetes Mellitus, Type 1